Foley Partner Stephen Maebius was quoted in an article that appeared in BioWorld Today on September 12, 2011 titled “Passage of Patent Reform Bill is Just the Beginning.” Maebius discusses the America Invents Act, a major patent reform bill which he identifies as a wide scope of change that is likely to develop for several years as the courts interpret the Act in future patent lawsuits. Regarding biotech, he views the Act’s extension of the prior use defense as a potential benefit to a company that is developing a product but is not the first to file. Maebius adds that the Supreme Court will still need to resolve issues such as patent eligibility, which were not addressed by the reform.
People
Related News
25 July 2024
In the News
Donald Schroeder on Groff – ‘Supreme Court decision is inviting a more fact-based analysis’
Foley & Lardner LLP partner Donald Schroeder assessed the impact of the U.S. Supreme Court’s 2023 decision in a religious accommodation case as it returns to the district court in the Law360 article, “A Year After High Court Spotlight, Groff Case Still A Bellwether.”
24 July 2024
In the News
Louis Lehot Featured in Q&A on How Startups Can Prepare for IPO
Foley & Lardner LLP partner Louis Lehot features in the Q&A, "How startups can get in top shape for an IPO, according to Silicon Valley lawyer Louis Lehot," part of Business Insider's Road to IPO' series.
24 July 2024
In the News
Courtenay Brinckerhoff on Patent Cap in Drug Pricing – ‘Hard to predict if this will make a difference’
Foley & Lardner LLP partner Courtenay Brinckerhoff discussed a recent bill passed in the U.S. Senate aimed at lowering drug prices by limiting the number of patents that can be asserted in cases over biosimilars in the Law360 article, “Patent Cap In Drug Pricing Bill Seen As Having Muted Effect.”